MENLO PARK, Calif.,
Jan. 28, 2015 /PRNewswire/
-- BioPharmX Corporation (OTCQB: BPMX), a biotechnology
company focused on the development of novel drug delivery products
to address unmet needs in large, well-defined and underserved
markets, today announced the appointment of Michael Hubbard as a new independent member of
its board of directors. Hubbard, a seasoned financial
executive with a career in public accounting and auditing, will
also lead the company's audit committee. Hubbard's
appointment brings the board's total number of members to four.
"We are delighted with Mike's decision to join BioPharmX's board
of directors," said Jim Pekarsky,
chief executive officer and co-founder of BioPharmX. "His
breadth and depth of experience serving companies of all sizes from
venture-backed to Fortune 500 entities and across several sectors –
including life sciences – will be invaluable as we continue to
position BioPharmX for growth."
Throughout his career Hubbard had served as a senior audit
partner − at Deloitte & Touche LLP prior to retiring and also
at PricewaterhouseCoopers LLP. In these roles he served
private and publicly held clients across the life sciences, waste
management, construction, and technology sectors, advising domestic
and international issuer companies on complex transactions,
including 19 IPOs and numerous follow-on equity and debt
offerings. Hubbard holds a B.A. degree in Business
Administration with a concentration in Accounting and an MBA degree
from Washington State
University. He is a licensed CPA in the states of
Washington and California and is a certified (by Deloitte
& Touche LLP) practitioner of international financial reporting
standards.
About BioPharmX Corporation
BioPharmX Corporation
(OTCQB: BPMX) is a Silicon Valley-based biotechnology company,
which seeks to provide innovative products through unique,
proprietary platform technologies for prescription,
over-the-counter ("OTC"), and supplement applications in the
fast-growing health and wellness markets, including women's health,
dermatology, and otolaryngology (ears, nose & throat). To
learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
Statements in this news
release relating to the business of BioPharmX, which are not
historical facts, are "forward-looking statements." These
forward-looking statements may be identified by words such as
"expect," "anticipate," "believe," or similar expressions that are
intended to identify such forward-looking statements. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement and the risks and other
factors detailed in the company's filings with the Securities and
Exchange Commission (SEC). Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements. The forward-looking
statements included in this news release are made only as of the
date hereof and the company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
may be required under applicable securities law.
BioPharmX is a pending trademark of BioPharmX
Inc.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biopharmx-corporation-appoints-michael-hubbard-to-its-board-of-directors-300026850.html
SOURCE BioPharmX